Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanley Cohen

Showing results (91-100 of 116) with videos related to

Pageof 12
Sort By:
Gastroenterology|February 28, 2007
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in childrenJeffrey Hyams, Wallace Crandall, Subra Kugathasan, et al.
Current Medical Research and Opinion|January 19, 2011
Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extensionJeffrey Hyams, Thomas D Walters, Wallace Crandall, et al.
Arthritis and Rheumatism|October 19, 2011
A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate aloneJoel M Kremer, Stanley Cohen, Bethanie E Wilkinson, et al.
ACR Open Rheumatology|July 28, 2022
Safety and Biological Activity of Rozibafusp alfa, a Bispecific Inhibitor of Inducible Costimulator Ligand and B Cell Activating Factor, in Patients With Rheumatoid Arthritis: Results of a Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose StudyLubna Abuqayyas, Laurence E Cheng, Marcia Teixeira Dos Santos, et al.
The Journal of Rheumatology|March 1, 2003
Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trialArthur Kavanaugh, Mark Genovese, Jan Baughman, et al.
American Journal of Physical Medicine & Rehabilitation|June 16, 2022
A Conversation Between Past and Present Chairs of the American Board of Physical Medicine and Rehabilitation: Four Decades of History and the Future of Board CertificationJohn F Ditunno, B Stanley Cohen, John L Melvin, et al.
Journal of Comparative Effectiveness Research|February 17, 2023
Using multiple imputation of real-world data to estimate clinical remission in pediatric inflammatory bowel diseaseNanhua Zhang, Chunyan Liu, Steven J Steiner, et al.
Journal of Translational Medicine|April 17, 2012
Engaging basic scientists in translational research: identifying opportunities, overcoming obstaclesJennifer A Hobin, Anne M Deschamps, Richard Bockman, et al.
The New England Journal of Medicine|August 10, 2012
Tofacitinib or adalimumab versus placebo in rheumatoid arthritisRonald F van Vollenhoven, Roy Fleischmann, Stanley Cohen, et al.
Clinical and Experimental Rheumatology|December 21, 2019
Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan studyVibeke Strand, Désirée van der Heijde, Yoshiya Tanaka, et al.
Pageof 12

Showing results (91-100 of 116) with videos related to

Sort By:
Pageof 12
Gastroenterology|February 28, 2007
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in childrenJeffrey Hyams, Wallace Crandall, Subra Kugathasan, et al.
Current Medical Research and Opinion|January 19, 2011
Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extensionJeffrey Hyams, Thomas D Walters, Wallace Crandall, et al.
Arthritis and Rheumatism|October 19, 2011
A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate aloneJoel M Kremer, Stanley Cohen, Bethanie E Wilkinson, et al.
ACR Open Rheumatology|July 28, 2022
Safety and Biological Activity of Rozibafusp alfa, a Bispecific Inhibitor of Inducible Costimulator Ligand and B Cell Activating Factor, in Patients With Rheumatoid Arthritis: Results of a Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose StudyLubna Abuqayyas, Laurence E Cheng, Marcia Teixeira Dos Santos, et al.
The Journal of Rheumatology|March 1, 2003
Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trialArthur Kavanaugh, Mark Genovese, Jan Baughman, et al.
American Journal of Physical Medicine & Rehabilitation|June 16, 2022
A Conversation Between Past and Present Chairs of the American Board of Physical Medicine and Rehabilitation: Four Decades of History and the Future of Board CertificationJohn F Ditunno, B Stanley Cohen, John L Melvin, et al.
Journal of Comparative Effectiveness Research|February 17, 2023
Using multiple imputation of real-world data to estimate clinical remission in pediatric inflammatory bowel diseaseNanhua Zhang, Chunyan Liu, Steven J Steiner, et al.
Journal of Translational Medicine|April 17, 2012
Engaging basic scientists in translational research: identifying opportunities, overcoming obstaclesJennifer A Hobin, Anne M Deschamps, Richard Bockman, et al.
The New England Journal of Medicine|August 10, 2012
Tofacitinib or adalimumab versus placebo in rheumatoid arthritisRonald F van Vollenhoven, Roy Fleischmann, Stanley Cohen, et al.
Clinical and Experimental Rheumatology|December 21, 2019
Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan studyVibeke Strand, Désirée van der Heijde, Yoshiya Tanaka, et al.
Pageof 12